A Clinical Efficacy Study Of An Oral Tyrosine Kinase Inhibitor Of VEGFR-2 Given In Combination With Chemotherapy
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether CP-547,632, an oral VEGFR-2 tyrosine kinase
inhibitor when given in combination with chemotherapy (carboplatin and paclitaxel) is
effective in the treatment of advanced stage non-small cell lung cancer.